Stockscreener 앱 받기
9.9745
1.22%
0.1245
Kura Oncology Inc 주식(KURA)의 최신 뉴스
Can technical indicators confirm Kura Oncology Inc.’s reversalJuly 2025 Trade Ideas & AI Based Buy and Sell Signals - newser.com
How Kura Oncology Inc. stock reacts to Fed rate cutsForecast Cut & Free Growth Oriented Trading Recommendations - newser.com
Predicting Kura Oncology Inc. trend using moving averagesMarket Movers & AI Optimized Trading Strategy Guides - newser.com
Can Kura Oncology Inc. stock resist market sell offsWeekly Trade Recap & Daily Profit Maximizing Trade Tips - newser.com
Will Kura's Menin Inhibitor Deliver Where Other AML Therapies Fall Short? - RTTNews
How sustainable is Kura Oncology Inc. stock dividend payoutJuly 2025 Sector Moves & Community Consensus Trade Alerts - newser.com
Visual analytics tools that track Kura Oncology Inc. performanceJuly 2025 Outlook & Community Supported Trade Ideas - newser.com
What analysts say about Kura Oncology Inc stockPrice Channel Trading & Small Budget Trading Tips - earlytimes.in
Identifying reversal signals in Kura Oncology Inc.2025 Market Sentiment & Verified Technical Trade Signals - newser.com
Custom strategy builders for tracking Kura Oncology Inc.2025 Trade Ideas & Fast Gain Stock Tips - newser.com
Will Kura Oncology Inc. stock reach all time highs in 2025Exit Point & Weekly Watchlist for Hot Stocks - newser.com
Kura Oncology (NASDAQ:KURA) Rating Lowered to Strong Sell at Zacks Research - MarketBeat
Advanced analytics toolkit walkthrough for Kura Oncology Inc.Earnings Beat & High Accuracy Swing Trade Signals - newser.com
Kura Oncology (NASDAQ:KURA) Given "Sell (D-)" Rating at Weiss Ratings - MarketBeat
Kura Oncology Inc. recovery potential after sell offMarket Performance Summary & Verified Technical Signals - newser.com
Menin Inhibitors Drug Market Report 2025: Price, Sales & Clinical Trials Insights 2024-2028 - GlobeNewswire Inc.
How Kura Oncology Inc. stock reacts to bond yieldsEarnings Risk Summary & Free Weekly Watchlist of Top Performers - newser.com
Real time social sentiment graph for Kura Oncology Inc.Weekly Investment Report & Verified Entry Point Signals - newser.com
Kura Oncology (NASDAQ:KURA) Trading 8.9% HigherStill a Buy? - MarketBeat
Wealth Enhancement Advisory Services LLC Buys 35,779 Shares of Kura Oncology, Inc. $KURA - MarketBeat
What drives Kura Oncology Inc stock priceEarnings Growth Projections & High Yield Market Growth - earlytimes.in
Kura Oncology, Inc. Experiences Evaluation Revision Amidst Market Dynamics and Performance Indicators - Markets Mojo
What MACD signals say about Kura Oncology Inc.2025 Technical Patterns & Long-Term Safe Investment Plans - newser.com
Can Kura Oncology Inc. stock withstand economic slowdownJuly 2025 WrapUp & Community Trade Idea Sharing Platform - newser.com
Kura Oncology Reports Inducement Grants under Nasdaq Listing Rule 5635(4) - MarketScreener
Kura Oncology Inc. stock prediction for this week2025 Support & Resistance & Fast Entry Momentum Alerts - newser.com
How Kura Oncology Inc. stock performs in rate cut cyclesWall Street Watch & Low Risk High Reward Ideas - newser.com
Will Kura Oncology Inc. bounce back from current supportGap Up & Smart Investment Allocation Insights - newser.com
Is Kura Oncology Inc a good long term investmentCash Flow Trends & View Live Stock Forecasts Instantly - earlytimes.in
Kura Oncology (KURA) Grants Inducement Awards to New Employees - GuruFocus
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
122,250-Option Grant for New Hires: Kura Oncology Grants Options at $9.20, vesting over four years - Stock Titan
Applying chart zones and confluence areas to Kura Oncology Inc.Earnings Risk Report & High Yield Stock Recommendations - newser.com
Kura Oncology, Inc. Experiences Evaluation Revision Amid Mixed Market Performance Indicators - Markets Mojo
Kura Oncology at UBS Virtual Oncology Day: Strategic Advances in AML Treatment - Investing.com Canada
Kura Oncology and Kyowa Kirin Launch Clinical Trial Evaluating Dual Inhibition of NPM1 and FLT3 Mutations in Patients with Newly Diagnosed Acute Myeloid Leukemia - MarketScreener
Kura Oncology (KURA) Advances KOMET-007 Trial with First Patient Dosed - GuruFocus
Kura Oncology and Kyowa Kirin Launch Clinical Trial Evaluating Dual Inhibition of NPM1 and FLT3 Mutations in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) - The Manila Times
Kura Oncology and Kyowa Kirin Initiate KOMET-007 Trial Evaluating Ziftomenib in Combination with FLT3 Inhibitors for Frontline Treatment of AML - Quiver Quantitative
Kura Oncology stock maintains Market Outperform rating at Citizens JMP By Investing.com - Investing.com Canada
Kura Oncology, Inc. (NASDAQ:KURA) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Kura Oncology, Inc. (NASDAQ:KURA) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Kura Oncology’s (KURA) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
0.95%
자본화:
|
볼륨(24시간):